Supporting our current proposal that metformin might operate as a small-molecule inhibitor of SHMT2, metformin has recently been reported to mimic the ability of serine catabolism blockade to ameliorate disease progression in a murine model of neuromuscular Leigh syndrome [70]. This evidence concerns the gene SHMT2 and Leigh syndrome.